On April 25, Philips announced its first-quarter results of 2022 and provided several updates about the recall of certain Philips Respironics PAP devices, including the announcement that it has received a subpoena from the US Department of Justice to provide information related to events leading to the Respironics recall. Philips indicated that it is cooperating with the agency.

Philips also provided several other updates about the PAP recall:

  • Philips Respironics has more than tripled its weekly production output compared to 2020.
  • To date, Philips Respironics has produced more than 2.2 million repair kits and replacement devices.
  • The total expected units to be remediated have increased by approximately 300,000, primarily in the US. (This increases the global total to 5.5 million devices.)
  • Philips Respironics expects to complete over 90% of the production and shipments to customers in 2022.
  • Comprehensive testing and analyses related to the affected CPAP and BiPAP devices are expected to be completed in the second quarter of 2022.

In addition to providing updates in its first-quarter results, Philips issued a new report with a summary of polyester‐based polyurethane (PE‐PUR) sound abatement foam testing results and conclusions available to date. Previously, in March, Philips posted a second sleep and respiratory care bulletin for clinicians, which included insights to help patients understand new features available on the DreamStation 2 Auto CPAP Advanced device.